Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer

Gunter von Minckwitz, MD, PhD
Published: Thursday, Jul 06, 2017



Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.

There has been a safety analysis of the APHINITY trial that focused on the impact on the cardiac toxicity, which was shown to be very low, explains von Minckwitz.

The most significant grade 3 side effect that was experienced was diarrhea, states von Minckwitz. This was confined to the chemotherapy period of the trial.



Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.

There has been a safety analysis of the APHINITY trial that focused on the impact on the cardiac toxicity, which was shown to be very low, explains von Minckwitz.

The most significant grade 3 side effect that was experienced was diarrhea, states von Minckwitz. This was confined to the chemotherapy period of the trial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x